Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech Investors: Believing the Dream, Rewarding Phase III IPOs

This article was originally published in Start Up

Executive Summary

Valuation Watch: our analysis of US biotech companies that have gone public in the 2003-04 window shows that having a late-stage development project offers private investors the best step-ups.

You may also be interested in...

IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?

Valuation Watch: an analysis of pre-money step ups for the 2003-04 biotech IPO window demonstrates that public investors are favoring companies in some therapeutic areas over companies in other areas. CNS and jump-start technologies, for example, are doing well.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts